What happened

Shares of TherapeuticsMD (NASDAQ:TXMD), a commercial-stage biopharma focused on women's health, rose 16% as of 12:50 p.m. EST on Tuesday. The bullish move is most likely linked to the news that financial giant JP Morgan (NYSE:JPM) has taken a substantial equity position in the company.

So what

An SEC filing revealed today that JP Morgan now owns 19.7 million shares of TherapeuticsMD's common stock. That represents more than 7% of shares outstanding.

Three traders pointing at a computer screen and smiling

Image source: Getty Images.

Traders are bidding up shares of this beaten-down stock in response to the vote of confidence from the financial giant.

Now what

TherapeuticsMD currently has three approved products on the market --Imvexxy, Bijuva, and Annovera -- and management believes they have nearly $2 billion in combined sales potential. However, ramping up a commercial team is expensive, so TherapeuticsMD is currently rapidly burning through capital as it works to build demand for its products. 

JP Morgan clearly believes in TherapeuticsMD's potential. Only time will tell if that bullish call was the right move. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.